These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 10775736)
41. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Aaron LE; Morris TJ; Jahshan P; Reiz JL Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237 [TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Hughes DA; Dubois D Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493 [TBL] [Abstract][Full Text] [Related]
43. Trospium chloride for the treatment of overactive bladder with urge incontinence. Singh-Franco D; Machado C; Tuteja S; Zapantis A Clin Ther; 2005 May; 27(5):511-30. PubMed ID: 15978301 [TBL] [Abstract][Full Text] [Related]
44. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. Gittelman M; Weiss H; Seidman L J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352 [TBL] [Abstract][Full Text] [Related]
46. Transdermal oxybutynin: a new treatment for overactive bladder. Davila GW Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930 [TBL] [Abstract][Full Text] [Related]
47. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Youdim K; Kogan BA Urology; 2002 Mar; 59(3):428-32. PubMed ID: 11880086 [TBL] [Abstract][Full Text] [Related]
48. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816 [TBL] [Abstract][Full Text] [Related]
49. [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder]. Arango Toro O; Nohales Taurines G; Cortadellas Angel R; Castro Santamaría R; Gelabert Mas A Actas Urol Esp; 1998 Feb; 22(2):124-30. PubMed ID: 9586268 [TBL] [Abstract][Full Text] [Related]
50. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523 [TBL] [Abstract][Full Text] [Related]
52. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. Van Arendonk KJ; Knudson MJ; Austin JC; Cooper CS Urology; 2006 Oct; 68(4):862-5. PubMed ID: 17070368 [TBL] [Abstract][Full Text] [Related]
53. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. Malone-Lee J; Shaffu B; Anand C; Powell C J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895 [TBL] [Abstract][Full Text] [Related]
54. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo. Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H; Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779 [TBL] [Abstract][Full Text] [Related]
55. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Appell RA Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760 [TBL] [Abstract][Full Text] [Related]
56. Transdermal oxybutynin: for overactive bladder. Bang LM; Easthope SE; Perry CM Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892 [TBL] [Abstract][Full Text] [Related]
57. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Dmochowski RR; Sand PK; Zinner NR; Gittelman MC; Davila GW; Sanders SW; Urology; 2003 Aug; 62(2):237-42. PubMed ID: 12893326 [TBL] [Abstract][Full Text] [Related]
58. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. Tincello DG; Adams EJ; Sutherst JR; Richmond DH BJU Int; 2000 Mar; 85(4):416-20. PubMed ID: 10691817 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423 [TBL] [Abstract][Full Text] [Related]
60. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]